Beone Medicines Ltd. quarterly report, Q2 FY2019

Business context and reporting period

The filing is BeiGene, Ltd.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2019. The request metadata says “Beone Medicines Ltd.,” but the filing identifies the registrant as BeiGene, Ltd. BeiGene is a commercial-stage biotechnology company developing oncology medicines and selling three in-licensed cancer drugs in China.

Key financial metrics

Amounts below are in U.S. dollars; financial statement figures have been converted from thousands to millions.

• Q2 product revenue was from ABRAXANE, REVLIMID and VIDAZA sales in China. Product revenue grew 85% year over year in Q2 and 111% for the first half.
• Q2 collaboration revenue was $185.2M, including a one-time $150.0M payment from Celgene upon termination of the tislelizumab collaboration. The payment materially boosted reported revenue and reduced the reported operating loss.
• Product gross margin, calculated as net product revenue less product cost of sales, was approximately 69% in Q2 and 71% for the first half of 2019. This is not the company’s overall margin, which is affected by collaboration revenue.
• R&D expense was $228.8M in Q2 and $407.1M for the first half, up 39% and 49%, respectively. SG&A was $82.2M in Q2 and $139.9M for the first half, up 82% and 89%.
• At June 30, cash and cash equivalents were $918.9M, short-term investments $618.8M, and restricted cash $23.7M—about $1.56B excluding restricted cash, or $1.59B including it. Current assets were $1.76B and current liabilities $271.7M.
• Total bank loans were approximately $93.2M and the shareholder loan was $154.3M. The shareholder loan bears 8% interest and is due in 2023 unless converted earlier; a $8.7M bank-loan tranche was due September 30, 2019. The Guangzhou facility loan was fully drawn, with maturities from 2021 to 2027.
• Cash used in operations was $218.1M in the first half. Investing activities provided $364.4M, principally reflecting net maturities and sales of investments; financing activities provided $58.3M, including $43.7M in new long-term borrowing.

Material changes versus the prior comparable period

• Reported revenue rose sharply, primarily because of the Celgene termination payment and recognition of deferred collaboration amounts, as well as growth in China product sales. The $150.0M termination payment is nonrecurring.
• Despite higher R&D and SG&A spending, Q2 operating loss narrowed by $77.2M year over year; first-half operating loss narrowed by $14.3M. First-half net loss narrowed by $8.8M.
• Cash and cash equivalents increased to $918.9M from $712.9M at year-end 2018, while short-term investments declined to $618.8M from $1.07B, reflecting investment purchases and maturities/sales.
• Inventory rose to $49.0M from $16.2M, primarily due to purchases of REVLIMID and VIDAZA to meet import timing requirements. Property, plant and equipment rose to $212.7M from $157.1M, largely reflecting construction of the Guangzhou manufacturing facility.
• BeiGene adopted the new lease standard on January 1, 2019; it recognized operating lease right-of-use assets and liabilities. The filing says adoption did not affect operations or cash flows.

Outlook, management commentary, risks and contingencies

• Management expects product revenue to increase in 2019 as it expands promotion and reimbursement efforts for ABRAXANE and REVLIMID and continues VIDAZA commercialization in China. No numerical revenue or earnings guidance is provided.
• Management expects continued losses and rising R&D and SG&A as clinical programs advance, commercial operations expand, and the company prepares for potential launches. Based on its current operating plan, it expected available cash, cash equivalents and short-term investments to fund operating expenses and capital expenditures for at least 12 months after issuance of the financial statements; it also says additional funding will be needed to complete all planned development and commercialization.
• Key pipeline candidates include zanubrutinib, tislelizumab and pamiparib. After the June termination of its Celgene collaboration, BeiGene regained global development and commercialization rights to tislelizumab. The separate China distribution license for Celgene’s three marketed drugs was unaffected.
• The company entered a global co-development agreement with BioAtla for BA3071, including a $20.0M upfront payment, and formed majority-owned MapKure with SpringWorks to develop BGB-3245. The filing also reports $30.0M in first-half in-process R&D expense for upfront payments under the Ambrx and BioAtla agreements.
• Material risks include clinical-trial and regulatory uncertainty, product safety, manufacturing capacity and compliance, dependence on third-party suppliers and distributors, competition, financing needs, foreign-exchange and China currency restrictions, and evolving Chinese regulation. The new Human Genetic Resources Regulation took effect July 1, 2019; BeiGene said its implementation and impact on its research activities remained uncertain.
• At June 30, the company had $134.9M of purchase commitments and $16.2M of capital commitments. It reported no legal proceedings it believed would have a material adverse effect and no off-balance-sheet arrangements.
• Management reported disclosure controls effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

1. Confirm the issuer identity: the supplied metadata names “Beone Medicines Ltd.,” while this filing is for BeiGene, Ltd.
2. Separate recurring product and collaboration revenue from the one-time $150.0M Celgene termination payment when assessing growth and operating performance.
3. Track China sales, reimbursement, inventory levels and the economics of distributing Celgene’s products, including exposure to purchase minimums and reliance on a third-party distributor.
4. Monitor clinical, regulatory and safety milestones for the pipeline, and the effect of regained global tislelizumab rights on future development costs and commercial plans.
5. Assess cash burn against the company’s stated funding runway, planned development and commercialization spending, and contractual commitments; verify repayment and conversion terms for outstanding loans.
6. Follow the implementation of China’s Human Genetic Resources rules and any resulting effects on clinical trials, data transfers, approvals or intellectual property rights.